• For Institutions

    • Corporate Services
    • Developers
  • Download
  • Help
  • About

    • Company Profile
    • License & Regulatory
    • Media coverage
longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
All
Options & Futures
Funds
IPO Subscription
Structured Products
Investment Wiki
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List

RAPT Therapeutics(RAPT.US)

Overview
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Dec18
Analyst Initiates Buy Rating for RAPT Therapeutics
10:52
Nov7
RAPT Therapeutics released FY2025 9 Months earnings on November 6, 2025 (EST), actual revenue USD 0, actual EPS USD -1.9441
04:00
RAPT Therapeutics released FY2025 Q3 earnings on November 6 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.652 (forecast USD -0.8189)
04:00
Oct27
Rapt Therapeutics Launches 2B Phase Clinical Trial of OZUREPRUBART for Food Allergy Patients
13:32
Oct25
Slutsky Maintains Buy Rating on RAPT Therapeutics
14:36
Oct22
Smith Rates RAPT Therapeutics Strong Buy with Price Target at $48.63
08:52

Schedules & Filings

Schedules
Filings
Nov6
Earning Release(EST)

FY2025 Q3 Earning Release (USD) Net Income -17.58 M, EPS -0.652

Aug7
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Net Income -17.64 M, EPS -0.6546

Jun17
Reverse Stock Split(EST)

1-for-8 Reverse Stock Split

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
INBS
11.532
+181.27%
+7.430
ANGH
3.885
+67.46%
+1.560
ESHA
21.950
+52.64%
+7.570
ESHAR
0.2500
+47.06%
+0.080
NCL
0.2814
+45.05%
+0.087
ULY
3.740
+35.51%
+0.940
RDACR
0.2493
+31.21%
+0.059
SIDU
3.485
+30.52%
+0.780
DVLT
0.6684
+29.41%
+0.151
ORIS
1.565
+28.28%
+0.345
View More